Aureka Biotechnologies
- Company typePrivate
- Founded2023
- HeadquartersLaguna Hills, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
Aureka Biotechnologies firmographics
Firmographics- Name
- Aureka Biotechnologies
- Legal name
- Aureka Biotechnologies, Inc.
- Website
- https://aurekabio.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Aureka Biotechnologies industry classification
Industry- Product category
- AI-driven antibody therapeutics discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computer Systems Design and Related Services (54151), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
- akta.pro industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)AI/ML Platforms for Drug Discovery & Experiment OptimizationHealthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
Keywords
Where Aureka Biotechnologies is headquartered
LocationHeadquarters
- HQ city
- Laguna Hills
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Aureka Biotechnologies business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharma business development and NewCo cooperation deals: Revenue generated through business development agreements and NewCo cooperation arrangements with multiple multinational pharmaceutical companies. The company has achieved tens of millions of dollars in revenue via this motion. These are typically milestone-driven, partnership-based deals that monetize Aureka's platform output.
- Internal pipeline licensing / asset out-licensing: Aureka is developing eight proprietary antibody pipelines across cardiovascular metabolism, immunology and CNS disease areas. Future monetization expected through out-licensing of these proprietary assets to larger pharma partners, in addition to preparing two projects for clinical trials.
- Reagent antibody discovery services: Custom antibody discovery and engineering services for research reagent development, exemplified by the project with BD Biosciences to develop high-performance research reagents using Aureka's generative AI-empowered platform.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based / not publicly disclosed |
Go-to-market motion3 records
Distribution channels5 records
Marketing channels8 records
Aureka Biotechnologies product offering
Product offeringCore offering
Aureka Biotechnologies commercializes an integrated AI-driven antibody drug design platform — AuraIDE™ — that combines high-throughput synthetic biology (autonomous yeast-based hypermutation), single-cell microfluidic functional screening, and a geometric-aware protein language model with deep reinforcement learning in a closed-loop Generate-Test-Learn-Optimize cycle. The platform is delivered to multinational pharmaceutical and biotech clients via enterprise antibody discovery partnerships, NewCo cooperation agreements, and custom service engagements (e.g., the BD Biosciences reagent development project), and also underpins an internal pipeline of eight proprietary antibody therapeutics across cardiometabolic, immunology, and CNS disease areas.
Product overview
Aureka Biotechnologies sells a unified, integrated tech-bio discovery platform (centered on the AuraIDE™ AI-driven antibody drug design platform) composed of three interlocking modules: (1) a High-Throughput Synthetic Biology / Autonomous Evolution engine that mines, synthesizes and characterizes therapeutic candidates at scale; (2) a proprietary Single-Cell Functional Screening platform based on droplet-based microfluidics that produces indexable per-cell data; and (3) a Protein Geometric Language Model and Deep Reinforcement Learning engine that drives the Generate–Test–Learn–Optimize loop. Together these modules power both Aureka's internal pipeline of cardiometabolic and inflammatory antibody therapeutics (including BsABs, ADCs and receptor agonists) and external offerings such as the Bispecific Antibody Discovery Pipeline and the Reagent Antibody Development Service (used in its BD Biosciences collaboration).
Differentiator
Problem solved
Functional benefit
Brands
- AuraIDE™: AI-driven antibody drug design platform developed by Aureka Biotechnologies for accelerating antibody therapeutic discovery.
Products and services
- AuraIDE™ AI-driven antibody drug design platform Proprietary AI-driven antibody drug design and optimization platform combining large-scale multimodal data with generative AI for rational, multi-objective and de novo protein therapeutic design, including bispecific antibodies, ADCs, and candidates for challenging targets such as GPCRs.
- Bispecific Antibody (BsAB) Discovery Pipeline High-throughput BsAB discovery service screening 1,000s to 100,000s of bispecific/multispecific variants in a single experiment; supports T-cell engagers (BiTEs), TCR mimics, soluble TCRs, bispecific/biparatopic ADCs, protein degraders (PROTABs), cytokine mimics, fusion proteins, and multi-subunit membrane receptor modulators.
- Reagent Antibody Development Service Generative AI-empowered antibody discovery and engineering service used to develop high-performance research reagents, validated through the project with BD (Becton, Dickinson and Company).
- Pharma Antibody Discovery Partnerships and NewCo Cooperation Multi-year enterprise antibody discovery and NewCo cooperation engagements with multinational pharmaceutical companies that monetize Aureka's AuraIDE™ platform output via milestone-driven partnership deals.
- Internal Cardiometabolic, Immunology, and CNS Antibody Pipeline Proprietary internal pipeline of eight differentiated antibody therapeutics targeting cardiovascular metabolism, immunology, and CNS disease areas, intended for out-licensing to larger pharma partners and clinical development (two projects targeted for clinical trials by end of 2026).
Quantifiable outcome
- Drug discovery timeline reduced from months to weeks
- +4 more outcomes
Companies that use Aureka Biotechnologies
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Aureka Biotechnologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability9 records
Feature7 records
Aureka Biotechnologies partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core ecosystem partner, strategic advisor, minor, moderate, flagship strategic customer and flagship ecosystem partner.
- Biocom Californiacore ecosystem partnerAureka featured in Biocom California's Member Spotlight (December 4, 2025). Biocom is a California life-sciences industry association providing networking, partnering conferences (e.g., Global Life Science Partnering & Investor Conference), and member visibility.
- Dr. David W. Shen (Founder & CEO, Propeller Bio)strategic advisorJoined Aureka's Scientific Advisory Board (August 6, 2025). Dr. Shen brings experience in biopharmaceutical innovation, from scientific research to company building. He is Founder & CEO of Propeller Bio. His expertise will guide Aureka's mission to accelerate therapeutic discovery through AI and high-throughput biology.
- ZymeworksminorCo-presented in the ACRO Biosystems 'Building the Perfect Antibody-based Therapeutic' webinar (September 10, 2024) alongside Aureka Bio and ACRO Biosystems. Zymeworks presented on antibody engineering with AI-driven candidate selection optimization.
- ACRO BiosystemsmoderateCo-presented the 'Building the Perfect Antibody-based Therapeutic' webinar (September 10, 2024) with Aureka Bio and Zymeworks. ACRO Biosystems covered precision in antibody conjugation and ADC manufacturing tools. Also co-organized the ACROConnect Workshop at World ADC San Diego 2024.
- BD (Becton, Dickinson and Company) / BD Biosciencesflagship strategic customerAnnounced project (May 23, 2024) with BD, a leading global medical technology company, to harness Aureka's generative AI-empowered antibody discovery and engineering platform to develop high-performance research reagents for scientific research.
- NVIDIA (NVIDIA Inception)flagship ecosystem partnerAureka joined NVIDIA Inception (announced December 4, 2023), a program that nurtures startups revolutionizing industries with AI. Benefits include access to advanced NVIDIA hardware and software, NVIDIA Deep Learning Institute credits, preferred pricing, and technological assistance to scale Aureka's AI-driven drug discovery efforts.
- Dr. Peter M. Tessier (Albert M. Mattocks Professor, University of Michigan)strategic advisorJoined Aureka Biotechnologies' Scientific Advisory Board (October 19, 2023). Dr. Tessier holds the Albert M. Mattocks Professorship in Pharmaceutical Sciences and Chemical Engineering at the University of Michigan and is internationally recognized for expertise in protein engineering, biopharmaceuticals, computational biology and drug discovery.
Scale indicators9 records
Recent moves5 records
Expansion highlights7 records
Aureka Biotechnologies competitors and assessment
Company assessmentDirect peers
- BigHat Biosciences: BigHat Biosciences uses an AI-guided antibody design platform with high-throughput wet-lab characterization to engineer antibody candidates for pharma partners. Directly comparable in integrating machine learning with experimental data for next-generation antibody design.
- Adagene: Adagene is an AI-driven antibody discovery and development company using its Dynamic Precision Therapeutics platform to engineer antibody candidates against difficult oncology targets. Overlaps with Aureka in AI-driven antibody discovery and function-first design philosophy.
- Absci: Absci combines generative AI (zero-shot protein design) with high-throughput synthetic biology (soluency E. coli-based screening) to design and validate antibody therapeutics end-to-end. Closely parallel to Aureka's generative-AI-plus-wet-lab stack and pharma partnership GTM.
- Generate Biomedicines: Generate Biomedicines is a generative AI biotech (founded by Flagship Pioneering) developing protein therapeutics de novo — directly paralleling Aureka's generative antibody design approach and pharma-partnered business model.
- AbCellera Biologics: AbCellera operates a tech-bio platform for AI-driven antibody discovery, including its own wet-lab screening and a protein language model (like Aureka, it combines high-throughput biology with machine learning for therapeutic antibody generation). It is the most-cited comparable for Aureka's BD-and-pipeline business model.
- Adimab: Adimab operates one of the most established antibody discovery platforms used by major pharma partners, with a focus on bispecifics and challenging targets. Although more traditional (less AI-native than Aureka), it is a direct competitor for the same pharma BD and bispecific discovery deals.
Broad incumbents
- Insitro: Insitro applies machine learning to pharma discovery with a focus on data-driven biology and partnerships with large pharma (Genentech, Eli Lilly). Comparable in spirit to Aureka as a data + AI + biology platform pursuing pharma BD deals, though focused on small-molecule and target discovery rather than antibodies.
- Isomorphic Labs: Isomorphic Labs is Alphabet's drug discovery company applying DeepMind's protein-folding and AI capabilities to drug design. A broad incumbent whose capabilities overlap with Aureka's protein language model approach, with much greater capital and computational resources.
Emerging players
- Xaira Therapeutics: Xaira Therapeutics is a well-funded AI drug discovery startup (launched in 2024 with $1B) applying foundation models to protein design and small-molecule discovery. Comparable to Aureka in generative biology focus, though broader in scope and deeper-pocketed.
- Cradle Bio: Cradle uses generative AI for protein engineering, with applications spanning enzymes and therapeutics. Comparable to Aureka in its protein language model + iterative wet-lab learning approach, but with broader end-markets beyond antibodies.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Aureka Biotechnologies social profiles
Digital presenceAureka Biotechnologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Aureka Biotechnologies leadership team
Management profileNumber of profiles
Profiles4 records
Aureka Biotechnologies funding detail
Funding detailFunding overview
Funding rounds6 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Aureka Biotechnologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Aureka Biotechnologies
What does Aureka Biotechnologies do?
Aureka Biotechnologies commercializes an integrated AI-driven antibody drug design platform — AuraIDE™ — that combines high-throughput synthetic biology (autonomous yeast-based hypermutation), single-cell microfluidic functional screening, and a geometric-aware protein language model with deep reinforcement learning in a closed-loop Generate-Test-Learn-Optimize cycle. The platform is delivered to multinational pharmaceutical and biotech clients via enterprise antibody discovery partnerships, NewCo cooperation agreements, and custom service engagements (e.g., the BD Biosciences reagent development project), and also underpins an internal pipeline of eight proprietary antibody therapeutics across cardiometabolic, immunology, and CNS disease areas.
Is Aureka Biotechnologies a public or private company?
Aureka Biotechnologies is a private company. It is classified as venture growth investor backed and is currently operating.
When was Aureka Biotechnologies founded?
Aureka Biotechnologies was founded in 2023. It employs 11 to 50 people.
Where is Aureka Biotechnologies based?
Aureka Biotechnologies is headquartered in Laguna Hills, United States, in the North America region.
How does Aureka Biotechnologies make money?
Three revenue lines are on record. Pharma business development and NewCo cooperation deals are the primary driver. The others are internal pipeline licensing / asset out-licensing and reagent antibody discovery services.
Who are Aureka Biotechnologies's main competitors?
Direct peers on record are BigHat Biosciences, Adagene, Absci, Generate Biomedicines, AbCellera Biologics and Adimab. Broad incumbents are Insitro and Isomorphic Labs. Emerging players are Xaira Therapeutics and Cradle Bio.
Does Aureka Biotechnologies have an API?
No public API is recorded for Aureka Biotechnologies.
What industry is Aureka Biotechnologies in?
Aureka Biotechnologies's product category is AI-driven antibody therapeutics discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 8731.